Tacrolimus
- Generic Name
- Tacrolimus
- Brand Names
- Advagraf, Astagraf, Envarsus, Modigraf, Prograf, Protopic, Tacforius
- Drug Type
- Small Molecule
- Chemical Formula
- C44H69NO12
- CAS Number
- 104987-11-3
- Unique Ingredient Identifier
- Y5L2157C4J
- Background
Tacrolimus (also FK-506 or Fujimycin) is an immunosuppressive drug whose main use is after organ transplant to reduce the activity of the patient's immune system and so the risk of organ rejection. It is also used in a topical preparation in the treatment of severe atopic dermatitis, severe refractory uveitis after bone marrow transplants, and the skin condi...
- Indication
Immediate-release formulations of tacrolimus are indicated for the prophylaxis of organ rejection in adult and pediatric patients receiving allogeneic liver, kidney, heart, or lung transplants, in combination with other immunosuppressants. Extended-release formulations of tacrolimus are indicated for the prophylaxis of organ rejection in adult and pediatric ...
- Associated Conditions
- Graft-versus-host Disease (GVHD), Heart Transplant Rejection, Kidney Transplant Rejection, Liver Transplant Rejection, Lung Transplant Rejection, Oral Lichen Planus, Psoriasis, Pyoderma Gangrenosum, Rheumatoid Arthritis, Severe Atopic Dermatitis, Vitiligo, Moderate Atopic dermatitis
- Associated Therapies
- -
Treosulfan-Based Conditioning Regimen Before a Blood or Bone Marrow Transplant for the Treatment of Bone Marrow Failure Diseases (BMT CTN 1904)
- Conditions
- Diamond-Blackfan AnemiaHereditary Sideroblastic AnemiaParoxysmal Nocturnal HemoglobinuriaShwachman-Diamond SyndromeHematologic Neoplasm With Germline GATA2 MutationHematologic Neoplasm With Germline SAMD9 MutationHematologic Neoplasm With Germline SAMD9L MutationBone Marrow Failure SyndromeCongenital Amegakaryocytic Thrombocytopenia
- Interventions
- Drug: TreosulfanDrug: Fludarabine PhosphateDrug: TacrolimusDrug: MethotrexateBiological: Lapine T-Lymphocyte Immune GlobulinProcedure: Peripheral Blood Stem Cell TransplantationProcedure: Allogeneic Bone Marrow TransplantationOther: Quality-of-Life AssessmentProcedure: EchocardiographyProcedure: Multigated Acquisition ScanProcedure: Bone Marrow BiopsyProcedure: Bone Marrow AspirationProcedure: Biospecimen CollectionProcedure: X-Ray ImagingProcedure: Computed Tomography
- First Posted Date
- 2021-07-16
- Last Posted Date
- 2024-06-17
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 40
- Registration Number
- NCT04965597
- Locations
- 🇺🇸
Oregon Health & Science University, Portland, Oregon, United States
🇺🇸Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸Cohen Children's Hospital of NY, Queens, New York, United States
HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide
- Conditions
- Interventions
- Drug: BusulfanRadiation: Total-body irradiationDrug: MelphalanDrug: CyclophosphamideDrug: FludarabineProcedure: PBSC Hematopoietic Stem Cell Transplantation (HSCT)Procedure: Bone Marrow Hematopoietic Stem Cell TransplantationDrug: Post-transplant CyclophosphamideDrug: MesnaDrug: TacrolimusDrug: Mycophenolate MofetilOther: Patient-Reported Outcomes
- First Posted Date
- 2021-05-27
- Last Posted Date
- 2024-05-23
- Target Recruit Count
- 300
- Registration Number
- NCT04904588
- Locations
- 🇺🇸
Levine Cancer Institute, Charlotte, North Carolina, United States
🇺🇸Ohio State Medical Center, James Cancer Center, Columbus, Ohio, United States
🇺🇸City of Hope National Medical Center, Duarte, California, United States
Selective CD28 Blockade in Renal Transplant Recipients
- Locations
- 🇺🇸
Emory University Hospital, Atlanta, Georgia, United States
A Study to Evaluate the Benefits and Risks of Conversion of Existing Adolescent Kidney Transplant Recipients Aged 12 to <18 Years to a Belatacept-based Immunosuppressive Regimen as Compared to Continuation of a Calcineurin Inhibitor-based Regimen, and Their Adherence to Immunosuppressive Medications
- First Posted Date
- 2021-05-07
- Last Posted Date
- 2024-10-28
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 102
- Registration Number
- NCT04877288
- Locations
- 🇺🇸
Local Institution - 0038, Seattle, Washington, United States
🇺🇸Local Institution - 0045, Miami, Florida, United States
🇺🇸Local Institution - 0022, Hollywood, Florida, United States
Itacitinib for the Prevention of Graft Versus Host Disease
- Conditions
- Interventions
- First Posted Date
- 2021-04-26
- Last Posted Date
- 2024-10-24
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 31
- Registration Number
- NCT04859946
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Efficacy of Achieving Early Target Trough Levels of Tacrolimus Using CYP3A5 Guided Dosing Versus Weight-based Dosing in a Multi-ethnic Population of Kidney Transplant Recipients in Singapore
- Conditions
- Interventions
- First Posted Date
- 2021-04-01
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Singapore General Hospital
- Target Recruit Count
- 74
- Registration Number
- NCT04825262
- Locations
- 🇸🇬
Singapore General Hospital, Singapore, Singapore
Study to Assess the Effect of Sodium Zirconium Cyclosilicate on the Pharmacokinetics of Tacrolimus and Cyclosporin in Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2021-03-09
- Last Posted Date
- 2024-04-05
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 62
- Registration Number
- NCT04788641
- Locations
- 🇩🇪
Research Site, Berlin, Germany
Pre-transplant Immunosuppression and Donor Stem Cell Transplant for the Treatment of Severe Hemoglobinopathies
- Conditions
- Interventions
- First Posted Date
- 2021-03-02
- Last Posted Date
- 2024-10-24
- Lead Sponsor
- M.D. Anderson Cancer Center
- Registration Number
- NCT04776850
The Combination of Tacrolimus and High-dose Dexamethasone as First-line Treatment in Adult Immune Thrombocytopenia
- First Posted Date
- 2021-02-10
- Last Posted Date
- 2021-02-10
- Lead Sponsor
- Peking University People's Hospital
- Target Recruit Count
- 120
- Registration Number
- NCT04747080
- Locations
- 🇨🇳
Peking University People's Hospital, Beijing, China
Bioequivalence Study of Tacrolimus in Healthy Volunteers
- First Posted Date
- 2021-01-27
- Last Posted Date
- 2023-09-21
- Lead Sponsor
- Food and Drug Administration (FDA)
- Target Recruit Count
- 67
- Registration Number
- NCT04725682
- Locations
- 🇺🇸
BioPharma Services USA, Saint Louis, Missouri, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.